# Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

> **NCT00320489** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 524 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** olanzapine
- **DRUG:** olanzapine pamoate depot

## Key facts

- **NCT ID:** NCT00320489
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 524 (ACTUAL)
- **Last updated:** 2012-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00320489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00320489, "Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00320489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*